Scienmag

APRIL 8, 2021

Credit: IRB Barcelona In cancer, personalised medicine takes advantage of the unique genetic changes in an individual tumour to find its vulnerabilities and fight it. Many tumours have a higher number of mutations due to a antiviral defence mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations.

Scientist 53

Scientist DNA Genetics Medicine 53

Drug Discovery World

APRIL 18, 2023

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Dunn Award for Outstanding Achievement in Pathology in Cancer Research Another award highlight was the AACR James S.

Genetics 52

Genetics DNA Research Bioinformatics 52

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. Diversigen, Inc.

Research 40

Research Bioinformatics Scientist Medicine 40

Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Context . It also detected potential disease-causing variants in a further 3.9% of patients. . Official comments .

Genome 52

Genome Genomics Genetics Genetic Disease 52

XTalks

SEPTEMBER 28, 2020

The liquid biopsy will therefore help personalize medicines for patients based on the molecular features of their disease. The test involves isolating circulating tumor DNA in the blood and sequencing it to look for relevant gene mutations.

Gene 105

Gene DNA Life Science Genotype 105

Drug Discovery World

JULY 26, 2023

An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. Research increasingly demonstrates that within each discrete microbial environment (e.g., identifying single nucleotide polymorphisms or chromosomal rearrangements).

Medicine 52

Medicine Genome Genomics Bioinformatics 52

XTalks

JULY 19, 2021

The technology powering GeneCompass is already in use by some well-known commercial laboratories, research institutions, fertility clinics and hospitals,” said Alexander Bisignano, Phosphorus co-founder and CEO, in a press release. “We The Phosphorus GeneCompass test has a list price of $249.

Genetics 98

Genetics Genome Genomics Gene 98

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). These tumor-derived entities are used to derive genomic and proteomic data.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. At that time, we thought this would be the holy grail for medicine. Now, however, the field is changing with respect to genomic medicine. This allows for much lengthier reads.

Genome 107

Genome Genomics Medicine Gene 107

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

OCTOBER 25, 2023

DDW Editor Reece Armstrong speaks to Dr Darrell Green , Lecturer in RNA Biology Biomedical Research Centre Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. The second concept is largely in oncology.

Bioinformatics 115

Bioinformatics Genetics RNA Drugs 115

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

APRIL 29, 2024

Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research (CRO) industries. He has a PhD in Bioinformatics from the University of Cambridge.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

MARCH 20, 2021

Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. Highlight #1 Dr. Neil Ashley, the Single-Cell Core Facility Manager at the Weatherall Institute of Molecular Medicine (WIMM) in Oxford, U.K., Vandesompele is a research. presented the.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. In a boone for Slonim’s research focus, the year 2020 has made this molecule a household name.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52